ClinicalTrials.gg
CompletedNCT04783766Updated Jan 24, 2025

Safety, Tolerability and Pharmacokinetics Study of CK-3773274

A Phase 1 interventional study of CK-3773274 and Placebo in Obstructive Hypertrophic Cardiomyopathy and Healthy Adult Subjects, sponsored by Corxel Pharmaceuticals. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Corxel Pharmaceuticals · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2021, 5 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.

Enrollment
11th of 11
28 · median 96
Started
2021
with 1 other
Phase 1
2 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
2 of 11
Corxel Pharmaceuticals

Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 3rd registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aficamten

aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purposes of this study are to:

  1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese healthy adult subjects.
  2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses.
  3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses.
  4. Determine the effect of doses of CK-3773274 on the pumping function of the heart.
  5. Evaluate the effect CYP2D6 genetic polymorphisms on how the body metabolizes CK-3773274.
03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy
  • Healthy Adult Subjects

Keywords

  • CK-274
  • Obstructive hypertrophic cardiomyopathy
  • CK-3773274
  • oHCM
  • aficamten
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Chinese males and females between 18 and 45 years of age, inclusive
  2. Body weight ≥50kg and (BMI) within 18 to 26 kg/m2, inclusive
  3. Acoustic windows adequate for accurate transthoracic echocardiograms
  4. Normal cardiac structure and function, as determined by the cardiologist, or if abnormalities are present, the finding is not as determined by the cardiologist
  5. ≥65 percent at screening, and LVEF ≥60 percent at Day-1
  6. Normal

Exclusion criteria

Exclusion Criteria:

  1. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs
  2. Subjects with breast implants that may impede echocardiography
  3. A illness within 4 weeks prior to admission to the CRU
  4. Inability to swallow tablets
  5. Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages within 48 hours prior to admission to the CRU
  6. Poor peripheral venous access
  7. Any blood donation within 60 days prior to admission to the CRU, or any plasma donation within 30 days prior to admission to the CRU, or receipt of blood products within 2 months prior to admission to the CRU
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    CK-3773274 for Single Ascending Dose (SAD) Cohorts

    Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of CK-3773274

    Drug: CK-3773274

  • Placebo comparator
    Placebo comparator for SAD Cohorts

    Subjects will be assigned to one of 2 planned dose cohorts and receive single doses of placebo comparator

    Drug: Placebo

  • Experimental
    CK-3773274 for Multiple Dose (MD) Cohort

    Subjects will receive multiple doses of CK-3773274

    Drug: CK-3773274

  • Placebo comparator
    Placebo comparator for MD Cohort

    Subjects will receive multiple doses of placebo comparator

    Drug: Placebo

Interventions

  • CK-3773274- Tablets

  • DrugPlacebo

    Placebo- Tablets

06

What researchers measure

Primary outcomes

  1. Subject incidence of Adverse Event (AE), Serious Adverse Event (SAE)

    Time frame: SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23

  2. Reduced Left Ventricular Ejection Fraction (LVEF)

    Time frame: SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23

Secondary outcomes

  1. Cmax of CK-3773274 after single and multiple ascending doses

    Time frame: SAD Cohorts: Day-1 - Day10; MD Cohort: Day-1 - Day 23

07

Study locations

1 site
  • Clinical Site
    Beijing, Beijing 100032, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2021, 3 months.

Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 5, 2021
StartActual
Apr 10, 2021
Primary completionActual
Aug 5, 2021
CompletionActual
Aug 5, 2021
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04783766
Lead sponsor
Corxel Pharmaceuticals
Collaborators
Cytokinetics
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Apr 10, 2021
Primary completion
Aug 5, 2021
Completion
Aug 5, 2021
Last update
Jan 24, 2025

Study contacts

Chen, MD
study director · Corxel Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aficamten

Start the discussion